The BD Onclarity™ HPV Assay can detect 14 high-risk HPV types and provide additional information to guide physician decision-making FRANKLIN LAKES, N.J., February 13, 2018 - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that it has received pre-market approval from the U.S. Food and...

New Test Provides Diagnostic Results Up to 10 Times Faster Than Traditional Tests FRANKLIN LAKES, N.J., and WAGENINGEN, The Netherlands, January 15, 2018 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, along with Check-Points Health B.V., announced today that the companies obtained CE Mark for a...

Experience the Advantage of Complete Medication Management at #ASHP17 BD Booth 721 ORLANDO, Dec. 4, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today revealed several technology innovations to further optimize the entire medication management process at this year's American Society of...

FRANKLIN LAKES, N.J., Nov. 16, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will launch its latest advancement in comprehensive medication management, BD HealthSight™ platform for enterprise medication management, which offers a unique combination of connective technologies, analytics and...

Fully-automated BD Phoenix™ CPO detect test helps detect dangerous pathogens FRANKLIN LAKES, N.J., September 26, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the launch1 of the first automated phenotypic test to detect and classify carbapenemase-producing organisms (CPO)....

FRANLIN LAKES, N.J., Sept. 19, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the introduction of the BD Ultra-Fine™ micro pen needle 6mm x 32G for use with leading pen injection devices, that is set for distribution starting September 2017. With this launch, BD is providing...

Extends BD MAX™ Enteric Panel Portfolio with latest Molecular Test that Targets Infectious Diarrhea
FRANKLIN LAKES, N.J., June 5, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that its newly developed molecular test for detecting harmful intestinal bacteria causing infectious...

Mass spectrometry identification solution may help hospitals manage antimicrobial resistance more effectively
FRANKLIN LAKES, N.J., Apr. 27, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the global distribution of a complete portfolio of products for mass spectrometry that...

FRANKLIN LAKES, NJ and MURRAY HILL, NJ (April 23, 2017) – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and C. R. Bard, Inc. (NYSE: BCR), a medical technology leader in the fields of vascular, urology, oncology and surgical specialty products, announced today a definitive agreement under which BD...

Expands Infusion Portfolio for Ambulatory, Home Care and Specialty Applications
FRANKLIN LAKES, N.J., April 4, 2017 – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has completed the acquisition of Israeli-based Caesarea Medical Electronics (CME), a global infusion pump systems...